Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 09, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,731,000 Ordinary shares of 25 pence each.
- Repurchase Price: 1,228.4036 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.00% of total voting rights).
- Shares in Issue: 5,270,207,874 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,731,000 repurchased shares. Consequently, the total number of shares in issue decreased to 5,270,207,874. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the updated total voting rights denominator (5,270,207,874 shares) for compliance with disclosure thresholds.
- Confirm the total number of Treasury shares held (474,194,158) and their impact on the 9.00% voting rights calculation.
- Review the specific authorization from the May 21, 2008 Annual General Meeting to ensure the repurchase was within approved limits.